Table 1.
Epidemiological information of the study population.
| NMOSD (n = 20) | MS (n = 17) | HD (n = 23) | SLE (n = 15) | |
|---|---|---|---|---|
| Age (median and interquartile range) | 48 (34.0–56.5) | 47 (36.0–51.0) | 29 (27.0–43.5) | 40 (31.0–48.0) |
| Sex (n and percentage female) | 17 (85.0) | 5 (29.4) | 15 (65.2) | 14 (93.3) |
| Time since disease onset (in years, median and interquartile range) | 7.0 (3.0–8.8) | 9.7 (4.6–15.4) | – | 13.0 (5.5–17.7) |
| Time since last relapse (in years, median and interquartile range) | n.d. | 3.4 (1.5–8.3) | – | n.d. |
| Clinical severity (EDSS for MS and NMOSD, SLEDAI for SLE median and interquartile range) | 3 (1.5–4.5) | 4 (2.0–5.0) | – | 5 (2.0 – 7.0) |
| Treatments (n, percentage) | Rituximab n = 8 (40.0), Azathioprine and untreated each n = 4 (20.0), Mycophenolate n = 3 (15.0), Teriflunomide n = 1 (5.0) | Dimethylfumarat n = 6 (35.3), Interferon beta n = 4 (23.4), untreated n = 3 (17.6), Daclizumab, intrathecal Steroids, Glatirameracetate and Fingolimod each n = 1 (5.9) | – | Prednisolone n = 15 (100.0), Hydroxychloroquine n = 7 (46.7), Mycophenolate n = 3 (20.0), Azathioprine, Methotrexate and Cyclosporine A each n = 2 (13.3), Rituximab n = 1 (6.67) |
| Autoantibody Status (n, percentage) | AQP-4 n = 8 (40.0) MOG n = 4 (20.0) |
– | – | – |
| % of LDGs (median and interquartile range) | 2.1 (1.1–4.1) | 0.9 (0.57–1.63) | 0.2 (0.2–0.4) | 4.3 (1.0–9.5) |
| % of CD16high LDGs (median and interquartile range) | 91.2 (77.2–94.9) | 87.8 (67.3–94.4) | 65.6 (53.7–79.9) | 84.6 (64.6–89.6) |
n.d. no data.